Your browser doesn't support javascript.
loading
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka, Yu; Nakai, Tokiko; Suzuki, Ayako; Kagawa, Yosuke; Noritake, Osamu; Taki, Tetsuro; Hashimoto, Hiroko; Sakai, Tetsuya; Shibata, Yuji; Izumi, Hiroki; Nosaki, Kaname; Udagawa, Hibiki; Zenke, Yoshitaka; Matsumoto, Shingo; Yoh, Kiyotaka; Miyazaki, Saori; Sakamoto, Naoya; Sakashita, Shingo; Kojima, Motohiro; Watanbe, Reiko; Tsuboi, Masahiro; Goto, Koichi; Ishii, Genichiro.
Afiliación
  • Tanaka Y; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Nakai T; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Suzuki A; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kagawa Y; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Noritake O; Department of Computational Biology and Medical Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
  • Taki T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Hashimoto H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakai T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Shibata Y; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Izumi H; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Nosaki K; Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Udagawa H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Zenke Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Miyazaki S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakamoto N; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Sakashita S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Kojima M; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Watanbe R; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Tsuboi M; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Goto K; Division of Pathology, Exploratory Oncology Research, and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Cancer Immunol Immunother ; 72(7): 2205-2215, 2023 Jul.
Article en En | MEDLINE | ID: mdl-36862151
ABSTRACT

INTRODUCTION:

This study aimed to clarify the correlation between the number of AMs and prognosis and to examine the gene expression of AMs in lung squamous cell carcinoma (SqCC).

METHODS:

We reviewed 124 stage I lung SqCC cases in our hospital and 139 stage I lung SqCC cases in The Cancer Genome Atlas (TCGA) cohort in this study. We counted the number of AMs in the peritumoral lung field (P-AMs) and in the lung field distant from the tumor (D-AMs). Moreover, we performed a novel ex vivo bronchoalveolar lavage fluid (BALF) analysis to select AMs from surgically resected lung SqCC cases and examined the expression of IL10, CCL2, IL6, TGFß, and TNFα (n = 3).

RESULTS:

Patients with high P-AMs had significantly shorter overall survival (OS) (p < 0.01); however, patients with high D-AMs did not have significantly shorter OS. Moreover, in TCGA cohort, patients with high P-AMs had a significantly shorter OS (p < 0.01). In multivariate analysis, a higher number of P-AMs were an independent poor prognostic factor (p = 0.02). Ex vivo BALF analysis revealed that AMs collected from the tumor vicinity showed higher expression of IL10 and CCL2 than AMs from distant lung fields in all 3 cases (IL-10 2.2-, 3.0-, and 10.0-fold; CCL-2 3.0-, 3.1-, and 3.2-fold). Moreover, the addition of recombinant CCL2 significantly increased the proliferation of RERF-LC-AI, a lung SqCC cell line.

CONCLUSION:

The current results indicated the prognostic impact of the number of peritumoral AMs and suggested the importance of the peritumoral tumor microenvironment in lung SqCC progression.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Japón
...